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Practice guidelines are important tools for improving the delivery of evidence-based
practices and reducing inappropriate variation in current treatment approaches. This
study examined the degree to which guidelines targeted to the treatment of substance
use disorders or serious mental illness address treatment of co-occurring disorders.
Guidelines archived by the National Guideline Clearinghouse (NGC) were retrieved in
December 2007 and content analyzed. Nineteen pertinent guidelines were identified,
and 11 included recommendations regarding the assessment and/or treatment of co-
occurring disorders. None of the guidelines making recommendations for treatment of
co-occurring disorders included outcomes that clearly targeted both substance use and
mental health disorders. Limitations and implications of this study are noted.
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Introduction
Substance use disorders (SUDs) and serious mental illnesses (SMIs) are significant public
health concerns. Approximately 22 million people in the United States were classified with
substance use or dependence in the past year (Epstein, Barker, Vorburger, and Murtha, 2004)
and 44 million people have experienced a SMI within the past year (National Institute of
Mental Health, 2001; US Department of Health and Human Services, 1999). Furthermore,
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the Substance Abuse and Mental Health Services Administration (SAMHSA) estimated in
1997 that the United States expended roughly $85 billion for these disorders, and 56% of
this amount was from public sources in that year alone (Mark, 2003; Mark et al., 2000).
Substance use disorders and serious mental illnesses frequently co-occur. According
to the US Surgeon General, 41 to 65% of persons with a lifetime SUD also have a history
of at least one SMI, and approximately 50% of persons with a lifetime SMI also have
a lifetime history of at least one SUD (US Department of Health and Human Services,
1999). Therefore, a maxim of contemporary epidemiological and services research is that
co-occurring disorders (also referred to as “comorbidity” and “dual diagnosis”) are the rule
rather than the exception (Stinson et al., 2005).
According to Drake and colleagues (2001), staged interventions, assertive outreach,
motivational interventions, counseling, social support, a long-term perspective, compre-
hensiveness, and cultural sensitivity and competency are the key components of effective
treatment for co-occurring disorders. Despite evidence that existing treatment approaches
can be effective (Brunette, Mueser, and Drake, 2004; Drake, Mercer-McFadden, Cueser,
McHugo, and Bond, 1998; Drake, Mueser, Brunette, and McHugo, 2004; Dumaine, 2003;
RachBeisel, Scott, and Dixon, 1990), only a small percentage of people with co-occurring
disorders receive effective treatment that addresses both disorders (Substance Abuse and
Mental Health Services Administration, 2002; Watkins, Burnam, Kung, and Paddock,
2001). This lamentable state of affairs may be attributable to the absence of brief screening
instruments (Lincoln, Liebschutz, Chernoff, Nguyen, and Amaro, 2006; Swartz and
Lurigio, 2006), which are critical for recognizing and subsequently treating disorders. Ser-
vices research has also documented limited availability of services targeting co-occurring
disorders (Ducharme, Knudsen, and Roman, 2006; Watkins et al., 2001), and absence
of training vis-à-vis assessment and treatment of comorbid conditions (Hall, Amodeo,
Shaffer, and Vander Bilt, 2000). Given the high costs and deleterious consequences
of co-occurring SUDs and SMIs, numerous governmental agencies have made quality
improvement in this practice area a priority (National Advisory Mental Health Council,
1999; National Institute of Drug Abuse, 2003; President’s New Freedom Commission on
MentalHealth, 2002; US Department of Health and Human Services, 2000).
The emergence of translational research is a direct result of increased awareness of the
pressing need to improve the system of care for dually diagnosed clients. Treatment guide-
lines are important components of broader strategies for moving research into practice and
changing provider practice patterns (Grimshaw et al., 2001, 2004). Treatment guidelines
are the systematically compiled statements of empirically tested knowledge and recom-
mended practices designed to help practitioners and clients select appropriate interventions
for specific clinical circumstances (Proctor and Rosen, 2003; Rosen and Proctor, 2003).
A key function of guidelines is to promote effective decision-making in situations that
are frequently encountered by service providers and their clients (Eddy, 1996). Clinical
practice guidelines have received considerable attention in the literature on evidence-based
practices and are one of the major tools for reducing treatment variability and translating
research into practice (Howard and Jensen, 1999; Institute of Medicine, 2006; Rosen and
Proctor, 2003; Walker, Howard, Lambert, and Suchinsky, 1994; Walker, Howard, Walker,
Lambert, and Suchinsky, 1995).
Research Objectives
Using a public open-access database of treatment guidelines, this study examined the
extent to which current guidelines targeting either SUDs or SMIs also addressed co-
occurring disorders. Co-occurring disorders are associated with a wide range of problems
1264 Perron et al.
requiring the attention of service providers from various disciplines. Therefore, this study
also examined the outcomes and intended audience targeted in guidelines that address
co-occurring SUDS and SMIs.
Methods
Data Source
This study examined guidelines archived by the National Guideline Clearinghouse (NGC;
http://www.guidelines.gov/), which is a public, open-access database of treatment guide-
lines. The NGC is sponsored by the Agency for Healthcare Research and Quality (AHRQ)
of the US Department of Health and Human Services. It was originally created by AHRQ
in partnership with the American Medical Association and the American Association of
Health Plans (now America’s Health Insurance Plans). Advantages of this resource are that
guidelines are presented in a standardized format, located in a single database, and freely
available, thereby reducing the burden of searching for and retrieving guidelines. The NGC
is the only coordinated effort to organize and disseminate practice guidelines in this fashion.
This database also contains guidelines produced by the major health-related organizations,
including the American Medical Association, the American Psychiatric Association, and
the Department of Veterans Affairs. At the time of writing this report, the database included
2,264 guidelines.
Search Definitions
In this study, “substance use disorders” included abuse or dependence based on the criteria
of the DSM-IV-TR (American Psychiatric Association, 2000). “Substances” of abuse were
alcohol and those psychoactive drugs identified in DSM-IV-TR (Brunette et al., 2004). The
specific SMIs targeted in this study were those associated with significant disability and
that were widely prevalent and commonly treated within the public mental health system:
schizophrenia-spectrum disorders, bipolar disorder, and major depression (Drake et al.,
2001).
“Co-occurring disorders” referred to the simultaneous presentation of a substance use
disorder and a serious mental illness. This usage is synonymous with other commonly
used terms such as “dual diagnosis,” “dual disorders,” “co-morbidity,” and “coexisting
disorders.”
Search Procedures
A computerized bibliographic search for guidelines of the NGC database was conducted
on December 1, 2007. The NGC database does not provide the facilities to conduct
complex searches containing Boolean operators. Thus, the procedure involved a broad-
based search using the following key words: “substance abuse,” “bipolar disorder,”
“depression,” and “schizophrenia.” This search procedure proved to be comprehensive.
Specifically, it returned guidelines that were relevant to the study purpose and numerous
guidelines that were irrelevant. The search strategy also returned a large number of
duplicate guidelines. For example, the search for schizophrenia guidelines returned many
depression guidelines. Subsequent searches using other synonymous keywords (e.g.,
major depressive disorder, psychosis, schizoaffective disorder, substance dependence,
drug abuse) did not return additional unique guidelines. Finally, a search for guidelines
targeting “co-occurring disorders” and its various synonyms (e.g., dual diagnosis, dual
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disorders, co-morbidity, and coexisting disorders) did not produce any additional unique
guidelines.
A preliminary review indicated that the available guidelines for SUDs and SMIs were
very heterogenous, targeting a variety of different populations and multiple disorders. In
order to produce a set of guidelines that were comparable with respect to study aims, a set
of inclusion and exclusion criteria was applied. Each criterion and the number of guidelines
excluded at each step are summarized in Table 1. The criteria and justification are as follows.
Guidelines were limited to adult treatment (age 17 to 44 years), given the prevalence of
the disorders and treatment varies considerably with different age groups. Guidelines were
excluded if they were not published by a US organization, since the system of care can
largely determine the treatment possibilities. Guidelines were also excluded if they did not
specifically address the target SUDs or SMIs as primary disorders. For example, guidelines
were excluded that considered SUDs or SMIs as secondary conditions associated with
other primary medical or social conditions (e.g., spinal cord injury, cardiovascular disease,
and domestic violence). As this study focused on interdisciplinary guidelines, guidelines
focusing specifically on medication management were also excluded from the review.
After excluding duplicate guidelines, the complete guidelines were downloaded as
portable document files (PDFs) and reviewed. The full list of search results was compiled
and the titles and summaries of each guideline were reviewed.
Coding
Guidelines were examined to determine whether they provided any treatment or screening
recommendations regarding co-occurring disorders. Treatment recommendations included
any clinical or psychosocial interventions specifically targeting co-occurring disorders.
Screening recommendations included any diagnostic or assessment procedures for co-
occurring disorders. Intended users of guidelines were categorized into two types: (1)
medical professionals (physicians, nurses, advanced practice nurses, pharmacists, physician
assistants, and other health care providers); (2) behavioral health clinicians (social workers,
psychologists, other mental health professionals, and substance use disorder treatment
providers). The different types of major outcomes targeted by each treatment guideline
were recorded as written.
Results
Recommendations for Co-Occurring Disorders
A total of 19 unique treatment guidelines were retrieved from the NGC database; nine
guidelines targeted SUDs and 10 targeted SMIs. These guidelines and their full citations
are provided in Appendix. For purposes of brevity, guidelines cited in the text are referred
to by the letter preceding the abbreviation in this Appendix.
Of the total guidelines, slightly more than half (58%, N = 11) contained at least one
recommendation with respect to assessment and/or treatment of co-occurring disorders (see
Table 2). While SMI guidelines had a higher proportion of co-occurring recommendations
than SUD guidelines (64% versus 55%, respectively), these differences were not significant
based on a Fisher’s exact test (p = .41). Bipolar disorder was the only type of disorder for
which there were no guidelines containing recommendations for a co-occurring disorder.
Across all guidelines that addressed co-occurring disorders, the most common recommen-
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(Guidelines D, B, G, H, M, O, P, Q). Forty-five (N = 5) of the guidelines recommended a
referral to a provider in the other (i.e., SUD or SMI) sector of care (Guidelines G, M, O, P,
R). Four guidelines recommended collaboration or cooperation across sectors (Guidelines
C, B, G, O), and one guideline recommended integrated SUD and SMI treatment (Guideline
R). It should be noted that two guidelines recommended “treatment” (Guidelines H, Q), but
additional information was not specified in terms of how treatment should be conducted
(e.g., collaboratively or in an integrated approach).
Multidisciplinary Guidelines
Medical professionals were the intended users of all 11 treatment guidelines that addressed
co-occurring disorders. Of these 11 guidelines, all but three (Guidelines O, Q, R) also listed
behavioral health professionals as intended users. Specifically, all guidelines for SUDs that
included recommendations for co-occurring disorders targeted both medical and behavioral
health providers. However, behavioral health providers were not listed as intended users on
two SMI guidelines for depression guidelines (Guideline O, Q) and one SMI guideline for
schizophrenia/psychosis (Guideline R).
Treatment Outcomes
With the exception of one (Guideline O), all guidelines listed treatment outcomes. The
number of outcomes targeted in these guidelines containing recommendations for co-
occurring disorders ranged from 3 to 11 (Mean = 5.9, SD = 3.0). Among this set of
guidelines, there were no clear outcomes that addressed both psychiatric symptomatology
and substance abuse-related outcomes, such as relapse. Three SMI guidelines that addressed
co-occurring disorders in some fashion referred to relapse (Guidelines M, P, S) but did not
indicate whether relapse referred to the SMI, SUD, or both. All guidelines that addressed
co-occurring disorders and described treatment outcomes targeted at least one psychosocial
outcome beyond clinical outcomes.
Discussion
This study reviewed the degree to which guidelines for SMIs and SUDs archived by the Na-
tional Guidelines Clearinghouse addressed treatment for co-occurring disorders. Slightly
more than half of the total guidelines retrieved included some type of recommendation
for the treatment of co-occurring disorders. These recommendations included assessment,
referrals, and collaboration with other professionals in the other sector of care. With the
exception of two guidelines (described below), these recommendations contained mini-
mal elaboration or specificity, leaving considerable room for interpretation on how the
recommendations should actually be implemented in routine practice.
Two guidelines are particularly noteworthy with respect to their specificity regarding
treatment for co-occurring disorders. This included the treatment guideline for schizophre-
nia, authored by the American Psychiatric Association (Guideline R). This guideline pro-
vided a comprehensive description of the major features of treatment (e.g., case manage-
ment, family interventions, rehabilitation, pharmacotherapy, and housing) and noted the
importance of the same clinicians treating both the SMI and SUD. Overall, these rec-
ommendations are consistent with the broader literature on comprehensive and integrated
treatment for this population (Drake et al., 1998, 2001). It should be noted that the treat-
ment guideline for bipolar disorder, also authored by the American Psychiatric Association
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(Guideline J), did not contain any treatment recommendations regarding SUDs. This is a
surprising finding, given the evidence suggesting that the rates of co-occurring alcohol and
drug problems among persons with bipolar disorder are at least equal to or greater than the
rates among persons with schizophrenia (Robins and Regier, 1991).
The second guideline to address treatment targeted substance use disorders with co-
occurring psychiatric disorders (Guideline B). This is a comprehensive treatment guideline
that contains screening suggestions, essential components of treatment (e.g., psychoe-
ducation, double trouble groups, and community-based dual recovery mutual self-help
groups), and treatment strategies (e.g., motivational interviewing, contingency manage-
ment, relapse prevention, and assertive community treatment). This guideline also corre-
sponds to a larger treatment manual provided by the Center for Substance Abuse Treatment
(2005).
The majority of the guidelines targeting co-occurring disorders were intended for a
multidisciplinary audience of service providers. This reflects the wide recognition that
treating SUDs, SMIs, and these conditions as they co-occur requires coordination with
many different provider types. However, the outcomes targeted by the guidelines were
generally restricted to the primary focus of the single disorder, even though the assessment
and/or treatment issues addressed co-occurring disorders. This suggests that many of these
guidelines have limited utility for addressing the full range of problems and needs that are
commonly encountered among persons with co-occurring disorders.
Limitations and Generalizability
This systematic review was restricted to guidelines archived on the NGC. This excluded a
potentially large number of proprietary and nonproprietary guidelines that are available in
print and electronically. Thus, the generalizability of this study is limited. Additionally, it
was beyond the scope of this study to examine the quality and consistency of the recommen-
dations contained in the guidelines against the extant literature. Despite these limitations,
it is important to emphasize that the NGC remains as one of the largest (or the largest)
data base that provides readily obtainable guidelines from major organizations that are
free.
Conclusions
Treatment guidelines can play an important role in implementing evidence-based practices
and changing provider practice patterns. Two guidelines that provide very specific infor-
mation for treating co-occurring disorders were located. Although the current guidelines
are limited, the NGC provides an infrastructure that makes guidelines widely available
without charge. Additional efforts are needed to improve existing guidelines to better ad-
dress co-occurring disorders. Without such guidelines, practitioners may fail to screen for
and identify the presence of co-occurring SUDs and SMIs. Furthermore, in addition to
screening, comprehensive empirically based treatment guidelines are necessary to inform
practitioners of integrated treatment methods. As existing research suggests, outcomes for
primary presenting disorders are likely to be improved through proper screening and treat-
ment (Baethge et al., 2005; Haywood et al., 1995; Mangrum, Spence, and Lopez, 2006;
Sacks, McKendrick, Sacks, Banks, and Harle, 2007). Additional research is also needed
to better understand and overcome barriers related to the implementation of treatment
guidelines and other forms of evidence-based practice (see Grimshaw, Eccles, and Tetroe,
2004).
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RÉSUMÉ
Les directives de pratique sont des outils importants pour améliorer la réalisation des
pratiques à base d’évidence et pour réduire le désaccord inconvenant des approches actuelles
de traitement. Cette étude a examiné le degré auquel les directives visées au traitement
des assuétudes à la drogue ou aux maladies mentales sérieuses abordent le traitement
des problèmes coexistants. Les directives archivées par le Centre d’Information National
des Directives ont été répertoriées en décembre 2007 et analysées. Dix-neuf directives
pertinentes ont été identifiées, et 11 d’entre elles ont inclus des recommandations concernant
l’évaluation et/ou le traitement des problèmes coexistants. Aucune des directives faisant
des recommandations pour le traitement des problèmes coexistants n’a inclus de résultats
qui ont clairement visé à la fois les assuétudes à la drogue et les troubles mentaux. Les
limitations et les implications de cette étude sont notées.
Mots clés : Directives de traitement, diagnostic double, problèmes coexistants
RESUMEN
Las pautas de práctica son herramientas importantes para mejorar la entrega de prácticas
fundadas en pruebas y para reducir la variación inapropiada que existe en las métodos
actuales. Ésta investigación examinó hasta qué punto las pautas dirigidas al tratamiento
de la drogadicción o de la enfermedad mental consideran el tratamiento de trastornos co-
existentes. Las pautas archivadas por el Centro de Información Nacional para las Pautas
fueron fueron recuperadas en diciembre del 2007 y analizadas. Diecinueve pautas perti-
nentes fueron identificadas, y once incluyeron recomendaciones sobre la evaluación y/o
tratamiento de los trastornos coexistentes. Ninguna de las pautas con recomendaciones
para el tratamiento de los trastornos coexistentes incluyó resultados que se dirigieron di-
rectamente a tanto la drogadicción como las enfermedades mentales. Las limitaciones e
implicaciones de esta investigación son notadas.
Palabras Claves: Pautas de práctica, diagnostico doble, trastornos coexistentes
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Glossary
Co-occurring disorders: “Co-occurring disorders” in this study refer to the simultaneous
presentation of a substance use disorder and a serious mental illness. This usage is syn-
onymous with other commonly used terms such as “dual diagnosis,” “dual disorders,”
“co-morbidity,” and “coexisting disorders.”
Treatment guidelines: “Treatment guidelines” are systematically compiled statements
of empirically tested knowledge and recommended practices designed to help practitioners
and clients select appropriate interventions for specific clinical circumstances.
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